These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 30679233

  • 21. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 22. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
    Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP.
    Semin Arthritis Rheum; 2010 Jun; 39(6):425-41. PubMed ID: 20223500
    [Abstract] [Full Text] [Related]

  • 23. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
    Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1916-1926. PubMed ID: 31745566
    [Abstract] [Full Text] [Related]

  • 24. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
    Endo Y, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Koga T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Yoshitama T, Eiraku N, Matsuoka N, Okada A, Fujikawa K, Hamada H, Tsuru T, Nagano S, Arinobu Y, Hidaka T, Tada Y, Kawakami A.
    Immunol Med; 2020 Sep 01; 43(3):115-120. PubMed ID: 32393150
    [Abstract] [Full Text] [Related]

  • 25. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F, Yun H, Bernatsky S, Curtis JR.
    Arthritis Rheumatol; 2016 Nov 01; 68(11):2612-2617. PubMed ID: 27213279
    [Abstract] [Full Text] [Related]

  • 26. Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.
    Pugliesi A, de Oliveira AB, Oliveira AB, Xavier R, da Mota LMH, Bertolo MB, Gonzalez-Gay MA, Citera G, de Carvalho LSF.
    Adv Rheumatol; 2023 Jul 06; 63(1):30. PubMed ID: 37415193
    [Abstract] [Full Text] [Related]

  • 27. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG.
    PLoS One; 2015 Jul 06; 10(6):e0130709. PubMed ID: 26114946
    [Abstract] [Full Text] [Related]

  • 28. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A, Park EH, Dong YH, Ha YJ, Lee YJ, Lee EB, Song YW, Kang EH.
    Osteoporos Int; 2020 Nov 06; 31(11):2131-2139. PubMed ID: 32514765
    [Abstract] [Full Text] [Related]

  • 29. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR.
    Arthritis Rheumatol; 2016 Jan 06; 68(1):56-66. PubMed ID: 26315675
    [Abstract] [Full Text] [Related]

  • 30. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld JP, Coupal L.
    Arthritis Res Ther; 2019 Jun 06; 21(1):138. PubMed ID: 31171024
    [Abstract] [Full Text] [Related]

  • 31. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.
    Arthritis Res Ther; 2016 Dec 01; 18(1):280. PubMed ID: 27906048
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 01; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar 01; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 34. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, Chung E, Barrett R, Button P.
    Int J Rheum Dis; 2018 Aug 01; 21(8):1581-1590. PubMed ID: 29205926
    [Abstract] [Full Text] [Related]

  • 35. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G.
    Clin Rheumatol; 2018 Feb 01; 37(2):315-321. PubMed ID: 28980085
    [Abstract] [Full Text] [Related]

  • 36. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.
    Rheumatology (Oxford); 2014 Sep 01; 53(9):1664-8. PubMed ID: 24729445
    [Abstract] [Full Text] [Related]

  • 37. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
    Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM.
    Arthritis Res Ther; 2015 Sep 18; 17(1):256. PubMed ID: 26382589
    [Abstract] [Full Text] [Related]

  • 38. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
    Schoels M, Aletaha D, Smolen JS, Wong JB.
    Ann Rheum Dis; 2012 Aug 18; 71(8):1303-8. PubMed ID: 22294630
    [Abstract] [Full Text] [Related]

  • 39. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    Iking-Konert C, von Hinüber U, Richter C, Schwenke H, Gürtler I, Kästner P, Klapperich B, Peters MA, Burmester GR.
    Rheumatology (Oxford); 2016 Apr 18; 55(4):624-35. PubMed ID: 26515959
    [Abstract] [Full Text] [Related]

  • 40. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N, Betts KA, Messali AJ, Skup M, Garg V.
    Clin Ther; 2017 Aug 18; 39(8):1618-1627. PubMed ID: 28729087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.